June 13, 2024 - $Biorestorative Therapies (BRTX.US)$shares soar 40.37% to $1.895 in intraday trading on Thursday. The company announced that it has held discussions with a commercial stage regenerative medicine company regarding its allogeneic, off-the-shelf ThermoStem metabolic intellectual property.

Previously published preclinical data showed a clonogenic population of metabolically active brown adipose tissue stem cells that can be expanded in vitro and exhibit multilineage differentiation potential. These cells functionally differentiate into metabolically active brown adipocytes, and thus could represent a new modality for the treatment of obesity and related metabolic disorders.

BioRestorative developed a 3D Porous Extracellular Matrix-Derived Scaffold for effective cell delivery, and data obtained in high-fat fed NOD-SCID mice transplanted with differentiated cells showed significant reductions in weight, triglyceride, and blood glucose levels compared to saline-only injected controls. BioRestorative's CEO, Lance Alstodt, said that the company is pleased to be engaging in substantive licensing discussions with a commercial stage regenerative medicine company, and that the discussions were a positive reflection of the company's pioneering animal studies. No assurances have been given that a license agreement will be entered into.

About BioRestorative Therapies, Inc.

BioRestorative develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. As described below, our two core clinical development programs relate to the treatment of disc/spine disease and metabolic disorders.